Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anixa BiosciencesANIX -4.37%31 EV-to-OCF is -13.61 as of Aug. 10, 2026. GuruFocus rates ANIX with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,405 Biotechnology companies, Anixa Biosciences ranks better than 75.66% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Anixa Biosciences's Enterprise Value is $96.84 Mil.
Anixa Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Apr. 2026 was $-7.12 Mil. Therefore, Anixa Biosciences's EV-to-OCF for today is -13.61.
The historical rank and industry rank for Anixa Biosciences's EV-to-OCF or its related term are showing as below:
ANIX'
s EV-to-OCF Range Over the Past 10 Years
Min: -29.63 Med: -12.23 Max: -1.36
Current: -13.61
During the past 13 years, the highest EV-to-OCF of Anixa Biosciences was -1.36. The lowest was -29.63. And the median was -12.23.
ANIX's EV-to-OCF is ranked better than 75.66% of 1405
companies
in the Biotechnology industry
Industry Median: -3.45
vs ANIX: -13.61
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Anixa Biosciences's PE Ratio (TTM) for today is calculated as:
Anixa Biosciences's share price for today is $3.28.
Anixa Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.310.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Anixa Biosciences EV-to-OCF Related Terms
Anixa Biosciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Anixa Biosciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Anixa Biosciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anixa Biosciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anixa Biosciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Anixa Biosciences's EV-to-OCF falls into.
Anixa Biosciences's current Enterprise Value is $96.84 Mil.
Anixa Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anixa Biosciences (ANIX) has a EV-to-OCF of -13.61 as of Aug. 10, 2026. According to the industry distribution chart, Anixa Biosciences ranks #342 out of 1405 companies in the Biotechnology industry, placing it in the top 24.3%.
Is Anixa Biosciences' EV-to-OCF too high?
Anixa Biosciences' current EV-to-OCF is -13.61. Based on the distribution chart, Anixa Biosciences ranks #342 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Anixa Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' EV-to-OCF compare to GUTS and CBUS?
According to the Biotechnology industry distribution chart, Anixa Biosciences ranks #342 out of 1405 companies for EV-to-OCF. This places Anixa Biosciences in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Anixa Biosciences's current EV-to-OCF is -13.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current EV-to-OCF of -13.61. The current EV-to-OCF is -13.61. Anixa Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current EV-to-OCF is -13.61 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
31GF Score
Get the complete analysis for ANIX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIX has been successfully added to your 
